Sanofi: positive data in multiple myeloma
(CercleFinance.com) - Sanofi has reported its latest positive results from the IKEMA Phase III clinical trial evaluating Sarclisa in multiple myeloma, as assessed by an independent committee and presented at the World Congress "Controversies in Mutliple Myeloma".
Sarclisa, in combination with carfilzomib and dexamethasone, provides an unprecedented increase in median progression-free survival (35.7 months versus 19.2 months) for patients with relapsed multiple myeloma treated with a proteasome inhibitor.
Further analysis, in accordance with the censoring rules recommended by the US FDA, showed that median progression-free survival increased from 20.8 to 41.7 months when Sarclisa was added to carfilzomib and dexamethasone, Sanofi added.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
Sarclisa, in combination with carfilzomib and dexamethasone, provides an unprecedented increase in median progression-free survival (35.7 months versus 19.2 months) for patients with relapsed multiple myeloma treated with a proteasome inhibitor.
Further analysis, in accordance with the censoring rules recommended by the US FDA, showed that median progression-free survival increased from 20.8 to 41.7 months when Sarclisa was added to carfilzomib and dexamethasone, Sanofi added.
Copyright (c) 2022 CercleFinance.com. All rights reserved.